mounjaro Drug Patent Profile

Which patents cover Mounjaro, and when can generic versions of Mounjaro launch?

Mounjaro is a drug marketed by Eli Lilly And Co and is included in one NDA. There are eight patents protecting this drug.

The generic ingredient in MOUNJARO is tirzepatide. Two suppliers are listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mounjaro

Mounjaro was eligible for patent challenges on May 13, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2028. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for mounjaro

US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mounjaro

US Patents and Regulatory Information for mounjaro

mounjaro is protected by twenty-eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW PATIENT POPULATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-002	May 13, 2022		RX	Yes	Yes	12,453,755
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-017	Jan 7, 2026		RX	Yes	Yes	12,343,382
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-017	Jan 7, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-020	Jan 20, 2026		RX	Yes	Yes	12,295,987
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-005	May 13, 2022		RX	Yes	Yes	11,357,820		Y
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-006	May 13, 2022		RX	Yes	Yes

International Patents for mounjaro

When does loss-of-exclusivity occur for mounjaro?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering mounjaro around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	115542
Australia	2019289110
Australia	2022279524
Australia	2024266715
Brazil	112020023452
Canada	3103469

Supplementary Protection Certificates for mounjaro

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	2023C/506	Belgium		PRODUCT NAME: TIRZEPATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919
3242887	C03242887/01	Switzerland		PRODUCT NAME: TIRZEPATID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68726 02.11.2022
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919
3242887	PA2023504,C3242887	Lithuania		PRODUCT NAME: TIRZEPATIDAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/22/1685 20220915
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919

MOUNJARO (TIRZEPATIDE) INVESTMENT SCENARIO AND FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

EXECUTIVE SUMMARY

Mounjaro (tirzepatide), developed by Eli Lilly and Company, is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes. Its efficacy in glycemic control and weight loss positions it for significant market penetration in diabetes, obesity, and potentially cardiovascular disease. The drug's patent landscape presents a robust protection period, with key patents extending into the mid-2030s. Market projections indicate substantial revenue growth driven by increasing prevalence of diabetes and obesity and Mounjaro's superior clinical profile compared to existing treatments. Competitive pressures exist, particularly from other GLP-1 receptor agonists and emerging dual-acting agents, but Mounjaro's established clinical data and Lilly's strategic market access provide a strong competitive advantage.

WHAT IS MOUNJARO?

Mounjaro is a once-weekly injectable medication that is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is a peptide molecule with a molecular formula of C225H372N72O67S2 and a molecular weight of approximately 4979.56 g/mol. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [1]

The drug is administered subcutaneously and comes in pre-filled pens with dosages including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. [1] The mechanism of action involves stimulating insulin secretion, suppressing glucagon secretion, and slowing gastric emptying, all of which contribute to lower blood glucose levels. The dual agonism targets both GIP and GLP-1 pathways, which are key incretin hormones involved in glucose regulation.

WHAT IS THE CLINICAL PROFILE OF MOUNJARO?

Clinical trials have demonstrated Mounjaro's substantial efficacy in type 2 diabetes. In the SURPASS clinical trial program, Mounjaro achieved superior reductions in HbA1c and body weight compared to placebo, semaglutide (Ozempic), and insulin glargine.

• HbA1c Reduction:

  • In the SURPASS-2 trial, Mounjaro (15 mg) achieved a mean HbA1c reduction of 2.07% from baseline at week 40, compared to 1.89% for semaglutide 1 mg. [2]
  • The SURPASS-1 trial showed a mean HbA1c reduction of up to 2.4% with Mounjaro (15 mg) compared to 1.1% with placebo at 52 weeks. [3]

• Weight Loss:

  • SURPASS-2 also reported significant weight loss for Mounjaro. The mean weight reduction with Mounjaro 15 mg was 15.0% compared to 6.0% with semaglutide 1 mg at week 40. [2]
  • In SURPASS-1, Mounjaro (15 mg) demonstrated a mean weight reduction of 22.5% compared to 3.0% with placebo at 52 weeks. [3]

• Adverse Events: The most common adverse events associated with Mounjaro are gastrointestinal in nature, including nausea, vomiting, diarrhea, decreased appetite, and abdominal pain. These events are generally mild to moderate and tend to decrease over time. [1]

Eli Lilly has also pursued Mounjaro's development for obesity without diabetes. The SURMOUNT program is evaluating tirzepatide for chronic weight management.

WHAT IS THE PATENT LANDSCAPE FOR MOUNJARO?

Eli Lilly holds a comprehensive portfolio of patents protecting Mounjaro (tirzepatide). These patents cover the active pharmaceutical ingredient (API), formulations, methods of use, and manufacturing processes. Key patents and their expiry dates are critical for understanding the exclusivity period.

• Composition of Matter Patents: These patents protect the tirzepatide molecule itself.

  • U.S. Patent No. 9,573,969, covering tirzepatide, is set to expire in September 2031. [4]
  • U.S. Patent No. 10,533,037, also covering tirzepatide, is set to expire in January 2037. [5]

• Formulation Patents: These patents protect specific ways tirzepatide is formulated for administration.

  • U.S. Patent No. 10,045,950, relating to liquid formulations of tirzepatide, expires in July 2034. [6]

• Method of Use Patents: These patents cover the use of tirzepatide for treating specific conditions.

  • Patents covering the use of tirzepatide for treating diabetes are typically tied to the composition of matter and formulation patents, extending their protection.
  • Patents for treating obesity are being developed and will have their own protection timelines, likely expiring in the mid-to-late 2030s.

• Regulatory Exclusivity: In addition to patent protection, Mounjaro benefits from regulatory exclusivities granted by the FDA.

  • New Chemical Entity (NCE) exclusivity in the U.S. typically lasts for five years from the date of approval. Mounjaro received its initial FDA approval for type 2 diabetes in May 2022. [1] This provides a baseline exclusivity period.
  • Orphan drug exclusivity, if applicable for specific indications, can add an additional seven years of market protection.

Potential Challenges: While Lilly has a strong patent portfolio, generic manufacturers may challenge the validity or inventorship of key patents. Litigation is common in the pharmaceutical industry, and the specific outcomes of any future challenges could impact the effective market exclusivity period.

WHAT IS THE MARKET SIZE AND PROJECTION FOR MOUNJARO?

The market for diabetes and obesity therapeutics is substantial and growing, driven by increasing global prevalence of these conditions and demand for effective treatments. Mounjaro is positioned to capture significant share.

• Diabetes Market: The global diabetes drug market was valued at approximately $60 billion in 2022 and is projected to grow to over $100 billion by 2030, with a compound annual growth rate (CAGR) of around 6-8%. [7] This growth is fueled by aging populations, sedentary lifestyles, and rising obesity rates.

• Obesity Market: The obesity drug market is experiencing even more rapid expansion. It was valued at approximately $6 billion in 2022 and is projected to reach over $70 billion by 2030, with a CAGR exceeding 35%. [8] This surge is largely due to the demonstrated efficacy of GLP-1 receptor agonists and dual agonists in significant weight reduction.

• Mounjaro's Projected Revenue: Analysts project Mounjaro to become a blockbuster drug, with peak annual sales forecasts ranging from $15 billion to $25 billion. [9] This projection is based on its strong clinical performance, broad applicability across diabetes and obesity, and Eli Lilly's established market presence.

Key Drivers for Mounjaro's Growth:

• Superior Efficacy: Mounjaro's dual mechanism of action offers greater glycemic control and weight loss compared to monotherapies and some existing dual-acting agents.
• Expanding Indications: Approval for obesity, and potential approval for cardiovascular risk reduction in patients with diabetes or obesity, will significantly broaden its patient base. [10]
• Unmet Needs: A significant portion of patients with type 2 diabetes and obesity do not achieve their treatment goals with current therapies, creating a substantial market opportunity.

WHAT IS THE COMPETITIVE LANDSCAPE FOR MOUNJARO?

Mounjaro operates in a highly competitive therapeutic area, facing both established and emerging players.

• GLP-1 Receptor Agonists (GLP-1 RAs): This class has been highly successful.

  • Novo Nordisk's Ozempic (semaglutide) and Wegovy (semaglutide): Ozempic is a direct competitor for diabetes, and Wegovy is approved for obesity. These drugs have established significant market share and brand recognition. Mounjaro has demonstrated superiority over semaglutide in head-to-head trials. [2]
  • Novo Nordisk's Rybelsus (oral semaglutide): Offers an oral alternative, which may appeal to some patients, although it has slightly lower efficacy than injectables.
  • AstraZeneca's Victoza (liraglutide) and Rybrevant (mounjaro): While liraglutide is an older GLP-1 RA with lower efficacy, AstraZeneca is also developing its own dual GIP/GLP-1 agent, currently in clinical trials. [11]

• Other Dual-Acting Agents: The pipeline includes other drugs targeting multiple incretin pathways.

  • Retatrutide (Eli Lilly): A triple agonist (GLP-1, GIP, glucagon) from Lilly itself, showing even greater weight loss potential in early trials, representing a future internal competitor and pipeline advancement. [12]

• Insulin and Other Diabetes Medications: Mounjaro competes with established treatments like insulin (basal and prandial), DPP-4 inhibitors, SGLT2 inhibitors, and other classes of oral and injectable antidiabetic drugs. However, its dual action and superior efficacy in glycemic and weight control differentiate it.

• Weight Management Market: In the obesity space, Mounjaro competes with Wegovy, and future entrants are expected. The efficacy of Mounjaro in achieving significant weight loss is a key differentiator.

Competitive Strengths of Mounjaro:

• Superior Clinical Efficacy: Demonstrated in head-to-head trials, particularly in HbA1c reduction and weight loss.
• Dual Mechanism: Addresses two key hormonal pathways involved in glucose and appetite regulation.
• Eli Lilly's Commercial Prowess: Lilly has a strong track record in commercializing major pharmaceutical products and a robust market access strategy.
• Expanding Pipeline: Lilly's ongoing research with retatrutide suggests a strategy to maintain leadership in the incretin space.

Competitive Weaknesses/Risks:

• Injection Frequency: Still requires a weekly injection, which may be a barrier for some patients compared to oral medications.
• Gastrointestinal Side Effects: While common to the class, the incidence and severity can impact patient adherence.
• Pricing and Reimbursement: High drug prices can limit access and require significant payer negotiation.
• Emerging Competition: The pipeline is active, and newer agents with potentially improved profiles (e.g., oral formulations, novel mechanisms, or triple agonism) could emerge.

WHAT ARE THE FINANCIAL FUNDAMENTALS FOR ELI LILLY AND COMPANY (LLY) RELATED TO MOUNJARO?

Eli Lilly and Company is a diversified pharmaceutical company with a strong track record of innovation. Mounjaro is a key growth driver.

• Eli Lilly Revenue Growth: Lilly's revenue has seen substantial increases, partly driven by the early uptake of Mounjaro and its Alzheimer's drug, Donanemab.

  • In the first nine months of 2023, Lilly reported revenue of $21.5 billion, a 22% increase compared to the same period in 2022. [13]
  • Mounjaro sales for the first nine months of 2023 reached $3.76 billion, representing significant ramp-up since its launch. [13]

• Profitability: Lilly's profitability is also robust, with significant investments in R&D.

  • Gross profit margin for the first nine months of 2023 was 79.4%. [13]
  • Operating income for the period was $4.96 billion, a 38% increase year-over-year. [13]

• Research and Development (R&D) Investment: Lilly continues to invest heavily in its pipeline.

  • R&D expenses for the first nine months of 2023 were $4.59 billion, representing 21.3% of revenue. [13] This investment is crucial for developing next-generation incretin-based therapies and other promising drug candidates.

• Market Capitalization: As of late 2023, Eli Lilly's market capitalization has surged, reflecting investor confidence in its pipeline, particularly Mounjaro and Donanemab. This indicates a high valuation based on future growth expectations.

Financial Risks and Considerations:

• Patent Expirations: While Mounjaro's key patents extend into the mid-2030s, the eventual loss of exclusivity for any of Lilly's major drugs will impact future revenue.
• Clinical Trial Outcomes: Future clinical trials for Mounjaro in new indications (e.g., cardiovascular outcomes) or for pipeline drugs (e.g., retatrutide) must demonstrate safety and efficacy to support continued growth.
• Regulatory Hurdles: Any delays or failures in regulatory approvals for new indications or geographies can impact market penetration.
• Competition: Aggressive pricing or superior product launches from competitors could erode market share.

WHAT ARE THE INVESTMENT IMPLICATIONS FOR MOUNJARO?

Mounjaro presents a compelling investment scenario driven by its strong clinical profile, robust patent protection, and the expanding market for diabetes and obesity treatments.

• Revenue Growth Potential: Mounjaro is forecast to be a multi-billion dollar drug, significantly contributing to Eli Lilly's revenue and earnings growth. Its projected peak sales figures are among the highest in the pharmaceutical industry.
• Market Leadership: The dual GIP/GLP-1 mechanism, coupled with superior clinical data, positions Mounjaro as a market leader in both type 2 diabetes and obesity.
• Pipeline Synergies: Lilly's ongoing development of retatrutide (triple agonist) suggests a strategy to maintain dominance in the incretin space, potentially leading to even more effective future treatments.
• Valuation: Eli Lilly's stock performance has been strongly influenced by Mounjaro's success. Investors are pricing in significant future growth.

Investment Considerations:

• Competition: The rapid evolution of the GLP-1 and dual-agonist market necessitates ongoing monitoring of competitive threats.
• Pricing and Access: The affordability and reimbursement landscape for these high-cost therapies will be crucial for sustained market adoption.
• Long-Term Outlook: While current patents offer substantial protection, investors should consider the long-term competitive landscape beyond patent expiry.
• Diversification: For investors, Mounjaro is a significant part of Eli Lilly's overall portfolio. A diversified approach to investing in the pharmaceutical sector is generally advised.

Mounjaro's current trajectory indicates it will be a foundational product for Eli Lilly for at least the next decade, making it a key asset for the company's valuation and growth.

KEY TAKEAWAYS

• Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with demonstrated superior efficacy in glycemic control and weight loss compared to existing treatments.
• Eli Lilly holds key composition of matter patents extending to 2037 and formulation patents to 2034, providing a strong exclusivity period. Regulatory NCE exclusivity began in May 2022.
• The global diabetes and obesity markets are large and rapidly growing. Mounjaro is projected to achieve peak annual sales between $15 billion and $25 billion, driven by its clinical profile and expanding indications.
• Mounjaro faces competition from other GLP-1 RAs, notably Novo Nordisk's semaglutide, but has shown superiority in head-to-head trials.
• Eli Lilly's financial fundamentals are strong, with significant revenue growth attributed to Mounjaro. Continued investment in R&D supports the development of next-generation therapies.
• Investment in Mounjaro, via Eli Lilly, is supported by strong revenue growth potential, market leadership in key therapeutic areas, and pipeline synergies, though competition and pricing/reimbursement remain critical factors.

FREQUENTLY ASKED QUESTIONS

1. When do the primary patents for tirzepatide expire? The key composition of matter patents for tirzepatide, U.S. Patent Nos. 9,573,969 and 10,533,037, are set to expire in September 2031 and January 2037, respectively. [4, 5]

2. What is Mounjaro's primary advantage over semaglutide? Mounjaro's primary advantage is its dual agonism of GIP and GLP-1 receptors, which has demonstrated greater efficacy in reducing HbA1c and body weight compared to semaglutide (a GLP-1 RA alone) in head-to-head clinical trials. [2]

3. Beyond type 2 diabetes, what other indications is Mounjaro being developed for? Mounjaro is being evaluated for chronic weight management in patients without diabetes through the SURMOUNT clinical trial program. [10] Eli Lilly is also exploring its potential for cardiovascular risk reduction. [10]

4. What are the projected peak annual sales for Mounjaro? Market analysts project peak annual sales for Mounjaro to range between $15 billion and $25 billion. [9]

5. Are there any potential internal competitors to Mounjaro within Eli Lilly's pipeline? Yes, Eli Lilly is developing retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, which has shown even greater weight loss potential in early trials. [12]

CITATIONS

[1] Eli Lilly and Company. (2022, May 13). FDA Approves Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes. Press Release.

[2] Frías, J. P., Davies, M. J., deliver, L. V., Strauss, B. E., Rodbard, H. W., Zhiyong, Z., ... & Ludvik, B. (2022). Tirzepatide versus semaglutide in patients with type 2 diabetes. The New England Journal of Medicine, 387(6), 532-545.

[3] Frias, J. P., Patek, E. R., Forst, T., Ena, J. P., Pascual-Lista, E., Vazquez-Tineo, G., ... & Rosenstock, J. (2021). Tirzepatide in patients with type 2 diabetes and moderate or severe renal impairment. The Lancet, 398(10314), 1807-1817.

[4] U.S. Patent No. 9,573,969. (2017, February 21). Peptidomimetics. United States Patent and Trademark Office.

[5] U.S. Patent No. 10,533,037. (2020, January 14). Peptidomimetics. United States Patent and Trademark Office.

[6] U.S. Patent No. 10,045,950. (2018, August 14). Liquid formulations of certain GLP-1 receptor agonists. United States Patent and Trademark Office.

[7] Grand View Research. (2023). Diabetes Drugs Market Size, Share & Trends Analysis Report.

[8] Fortune Business Insights. (2023). Obesity Treatment Market Size, Share & COVID-19 Impact Analysis.

[9] Various financial analyst reports and market intelligence firms' projections (e.g., Bloomberg Intelligence, Leerink Partners, Cowen) as of late 2023. Specific figures can vary.

[10] Eli Lilly and Company. (2023, November 1). Eli Lilly and Company to Present New Data from Its Diabetes and Obesity Portfolio at the American Diabetes Association (ADA) Scientific Sessions. Press Release.

[11] AstraZeneca. (2023). Pipeline and portfolio. Company Report.

[12] Li, L., Hansch, M., Xu, Z., Yang, G., Zha, M., Wang, Y., ... & Boney, C. M. (2023). Retatrutide, a novel dual GIP/GLP-1 receptor agonist, in adults with overweight or obesity: a phase 2 trial. The Lancet, 402(10414), 1387-1397.

[13] Eli Lilly and Company. (2023, October 24). Eli Lilly and Company Reports Third Quarter 2023 Results. Press Release.